PE20110837A1 - Suspension farmaceutica de liberacion doble - Google Patents

Suspension farmaceutica de liberacion doble

Info

Publication number
PE20110837A1
PE20110837A1 PE2011001337A PE2011001337A PE20110837A1 PE 20110837 A1 PE20110837 A1 PE 20110837A1 PE 2011001337 A PE2011001337 A PE 2011001337A PE 2011001337 A PE2011001337 A PE 2011001337A PE 20110837 A1 PE20110837 A1 PE 20110837A1
Authority
PE
Peru
Prior art keywords
understood
covered
pharmaceutical suspension
release pharmaceutical
double release
Prior art date
Application number
PE2011001337A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Sanju Dhawan
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of PE20110837A1 publication Critical patent/PE20110837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA SUSPENSION FARMACEUTICA ORAL DE LIBERACION DOBLE QUE COMPRENDE UNA FRACCION DE LIBERACION INMEDIATA EN FORMA DE SOLUCION, SUSPENSION O MICROGRANULOS NO CUBIERTOS Y UNA FRACCION DE LIBERACION SOSTENIDA EN FORMA DE MICROPARTICULAS RECUBIERTAS SUSPENDIDAS QUE COMPRENDE UN NUCLEO Y UN RECUBRIMIENTO, DONDE EL NUCLEO COMPRENDE UNO O MAS AGENTES ACTIVOS TAL COMO PARACETAMOL, INDOMETACINA, DICLOFENACO SODICO, ENTRE OTROS, UNO O MAS POLIMEROS INSOLUBLES EN AGUA Y UNO O MAS EXCIPIENTES. EL TAMANO DE LAS MICROPARTICULAS DEL NUCLEO SE ENCUENTRA EN EL INTERVALO DE 0,5 um A 2000 um
PE2011001337A 2009-01-09 2010-01-08 Suspension farmaceutica de liberacion doble PE20110837A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN30DE2009 2009-01-09

Publications (1)

Publication Number Publication Date
PE20110837A1 true PE20110837A1 (es) 2011-11-27

Family

ID=42541723

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001337A PE20110837A1 (es) 2009-01-09 2010-01-08 Suspension farmaceutica de liberacion doble

Country Status (10)

Country Link
US (1) US20110268808A1 (es)
EP (1) EP2385823A4 (es)
JP (1) JP2012514632A (es)
AU (1) AU2010211980A1 (es)
CO (1) CO6400182A2 (es)
MX (1) MX2011007399A (es)
PE (1) PE20110837A1 (es)
RU (1) RU2011133020A (es)
SG (1) SG172833A1 (es)
WO (1) WO2010089767A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
CA2859174C (en) * 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
US8927529B2 (en) 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
US9763928B2 (en) * 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
AU2015254875A1 (en) * 2014-05-01 2016-11-17 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
PL3137057T3 (pl) * 2014-05-01 2021-04-06 Sun Pharmaceutical Industries Ltd Kompozycje ciekłe metforminy o przedłużonym uwalnianiu
RU2017106010A (ru) 2014-07-30 2018-08-28 Сан Фармасьютикал Индастриз Лимитед Двухкамерная упаковка
PT3479823T (pt) 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
MX2019003257A (es) 2016-09-23 2019-06-10 Gruenenthal Gmbh Formulacion estable para la administracion parenteral de tapentadol.
WO2019070818A2 (en) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. SUSPENSION OF ENCAPSULATED PHARMACEUTICAL PRODUCTS AND METHODS OF MAKING AND USING SAME
EP3773490A4 (en) 2018-04-10 2021-12-22 Panacea Biomatx Inc. METHOD AND SYSTEM FOR MANUFACTURING PERSONALIZED NUTRITIONAL AND PHARMACEUTICAL FORMULATIONS USING ADDITIONAL MANUFACTURING
CN108926530A (zh) * 2018-08-17 2018-12-04 江苏科瑞达药业有限公司 一种具有高效混悬作用的对乙酰氨基酚液体制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258909B2 (en) * 2002-08-20 2010-07-08 Philera New Zealand Limited Dosage forms and related therapies
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
FR2872044B1 (fr) * 2004-06-28 2007-06-29 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
PE20080313A1 (es) * 2006-06-01 2008-04-10 Schering Corp Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
PE20080710A1 (es) * 2006-06-02 2008-08-07 Smithkline Beecham Corp Compuestos de tiofeno de bencimidazol
WO2008122993A1 (en) * 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles

Also Published As

Publication number Publication date
US20110268808A1 (en) 2011-11-03
CO6400182A2 (es) 2012-03-15
EP2385823A4 (en) 2014-02-12
WO2010089767A1 (en) 2010-08-12
MX2011007399A (es) 2011-11-18
AU2010211980A1 (en) 2011-08-25
EP2385823A1 (en) 2011-11-16
JP2012514632A (ja) 2012-06-28
RU2011133020A (ru) 2013-02-20
SG172833A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
PE20110837A1 (es) Suspension farmaceutica de liberacion doble
ITVA20110027A1 (it) Composizioni per la cura della persona
CL2016001940A1 (es) Composición farmacéutica que contiene un compuesto derivado de imidazo[1,5-a]indol, [1,2,4]triazolo[3,4-a]isoindol, [1,2,3]triazolo[5,1-a]isoindol ó 1,4-dihidroindeno[1,2-c] sustituidos y un segundo agente terapéutico; y su uso tratar la inmunosupresión mediada por indoleamina 2,3-dioxigenasa (ido), estimular la proliferación de células t, inhibir la degradación de triptófano en células que expresa ido, para tratar una enfermedad asociada con ido como una infección o cáncer (divisional de solicitud n° 2649-2015).
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
CO6450625A2 (es) Sistema intrauterino para uso en tratamiento médico
CR20120313A (es) Antagonistas de espiro-oxindol de mdm2
CO6511280A2 (es) Pastillas de gelatina blanda con nicotina
AR100006A1 (es) Derivados de tubulisina
CO6400190A2 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
AR086271A1 (es) Agente sanitario en forma de piezas
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
MX369742B (es) Formulación de liberación modificada.
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
PE20150888A1 (es) Composicion de difenidol de liberacion prolongada
TR201908151T4 (tr) İzoindolin türevleri.
PE20131064A1 (es) Preparacion de particulas recubiertas
AR088031A1 (es) Articulo absorbente
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
MX2015006011A (es) Pastilla medicinal a base de ibuprofeno sodico dihidratado.
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
TN2015000156A1 (en) Dispersible tablet

Legal Events

Date Code Title Description
FD Application declared void or lapsed